Mutant calreticulin–directed immunotherapies in myeloproliferative neoplasms

Blood Neoplasia 2026 Open access

Read full text
Authors: William L. Heaton, Matthew T. Jenkins, Nicole Arellano, Callie Brown, Srinivas K. Tantravahi, Shannon E. Elf
DOI: 10.1016/j.bneo.2026.100193
Cited by: 3
References: 57

Abstract

mutations result in the introduction of a neomorphic C-terminal tail that is absent from the normal proteome, which has positioned it as a compelling target for immunotherapeutic intervention. Early studies have demonstrated mutant CALR can elicit T-cell responses, laying the foundation for efforts to exploit this vulnerability through vaccines, antibody-based strategies, and T-cell-based therapies. Here, we summarize the current understanding of normal and mutant CALR biology, discuss progress in developing CALR-directed immunotherapies, and highlight the challenges and opportunities for translating these approaches into the clinic.

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Multiple Myeloma Research and Treatments Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Blood Neoplasia
Publisher
Elsevier BV
Volume
3
Issue
2
Pages
100193–100193
Publication date
14 January 2026
Language
EN